Pumping Up Dermatologic Drug Reformulation: A Review of How Proton Pump Inhibitors May Revolutionize Scleroderma Treatment.

Aaron Cheng, David G Cotter, Manisha Ahir, Mohammad A Khan, Mark D Bonnen, Yohannes T Ghebre

Abstract readReview

In one paragraph

Review in The Journal of clinical and aesthetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Aaron ChengMr. Cheng is with the Joe R. and Teresa Lozano Long School of Medicine at the University of Texas Health Science Center at San Antonio, San Antonio, Texas.

David G CotterDr. Cotter is with Las Vegas Dermatology and the University of Nevada Las Vegas School of Medicine, Las Vegas, Nevada.

Manisha AhirDr. Ahir is with the Cullen Eye Institute at Baylor College of Medicine, Houston, Texas.

Mohammad A KhanDr. Khan is with the Department of Radiation Oncology at the University of Texas Health Science Center at San Antonio, San Antonio, Texas.

Mark D BonnenDrs. Bonnen and Ghebre are with the Department of Radiation Oncology and the Mays Cancer Center at the University of Texas Health Science Center at San Antonio, San Antonio, Texas.

Yohannes T GhebreDrs. Bonnen and Ghebre are with the Department of Radiation Oncology and the Mays Cancer Center at the University of Texas Health Science Center at San Antonio, San Antonio, Texas.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Scleroderma is a rare and often debilitating connective tissue disorder of unknown etiology affecting the skin, lungs, and other visceral organs. Current medical therapies are limited and largely focused on symptoms, particularly in advanced disease. Recent preclinical studies have shown that topically reformulated proton pump inhibitors (PPIs) reduce inflammation and fibrosis, suggesting therapeutic potential in scleroderma. In this article, we explore the emerging role of PPIs as an adjuvant therapy in scleroderma. We also describe the key mechanisms of scleroderma and current therapeutic options and highlight how PPIs modulate molecular pathways central to fibrotic disease.

Indexed as

drug developmentdrug repurposingfibrosisProton pump inhibitorsscleroderma

Identifiers

PMID42027413

PMCPMC13102152

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.